Gent M - Search Results

1

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Furlan A, et al. Among authors: gent m. JAMA. 1999 Dec 1;282(21):2003-11. doi: 10.1001/jama.282.21.2003. JAMA. 1999. PMID: 10591382 Clinical Trial.

2

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial.

Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M. Kase CS, et al. Among authors: gent m. Neurology. 2001 Nov 13;57(9):1603-10. doi: 10.1212/wnl.57.9.1603. Neurology. 2001. PMID: 11706099 Clinical Trial.

3

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. del Zoppo GJ, et al. Among authors: gent m. Stroke. 1998 Jan;29(1):4-11. doi: 10.1161/01.str.29.1.4. Stroke. 1998. PMID: 9445320 Clinical Trial.

4

Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study.

Hill MD, Kent DM, Hinchey J, Rowley H, Buchan AM, Wechsler LR, Higashida RT, Fischbein NJ, Dillon WP, Gent M, Firszt CM, Schulz GA, Furlan AJ; PROACT-2 Investigators. Hill MD, et al. Among authors: gent m. Stroke. 2006 Sep;37(9):2322-5. doi: 10.1161/01.STR.0000237060.21472.47. Epub 2006 Aug 3. Stroke. 2006. PMID: 16888269

5

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Kearon C, et al. Among authors: gent m. JAMA. 2006 Aug 23;296(8):935-42. doi: 10.1001/jama.296.8.935. JAMA. 2006. PMID: 16926353 Clinical Trial.

6

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Connolly SJ, et al. Among authors: gent m. JAMA. 2006 Jan 11;295(2):165-71. doi: 10.1001/jama.295.2.165. JAMA. 2006. PMID: 16403928 Clinical Trial.

7

Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial.

Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, Morillo C, Gent M; VPS II Investigators. Connolly SJ, et al. Among authors: gent m. JAMA. 2003 May 7;289(17):2224-9. doi: 10.1001/jama.289.17.2224. JAMA. 2003. PMID: 12734133 Clinical Trial.

8

Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.

Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Heit JA, et al. Among authors: gent m. Ann Intern Med. 2000 Jun 6;132(11):853-61. doi: 10.7326/0003-4819-132-11-200006060-00002. Ann Intern Med. 2000. PMID: 10836911 Clinical Trial.

9

Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.

Haq A, Morgan CD, Wilson RF, Daly PA, Baigrie RS, White CW, Roberts R, Gent M, Armstrong PW. Haq A, et al. Among authors: gent m. Am J Cardiol. 1993 Aug 15;72(5):379-83. doi: 10.1016/0002-9149(93)91126-3. Am J Cardiol. 1993. PMID: 8352178 Clinical Trial.

10

A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.

Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. Levine M, et al. Among authors: gent m. Chest. 1990 Dec;98(6):1473-9. doi: 10.1378/chest.98.6.1473. Chest. 1990. PMID: 2123152 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

468 results

Search Page

Filters